LENZ Therapeutics, Inc.
LENZHealthcareNASDAQBiotechnology · Last scanned Sep 8, 2026
Scan Results
Daily timeframeLENZ Therapeutics, Inc. operates as a commercial pharmaceutical company that focuses on the development and commercialization of therapies to improve vision in the United States. The company carries a $187.3M market cap, placing it firmly in the micro-cap category. Its product candidates include VIZZ and LNZ101 for the treatment of presbyopia in adults.
Market Cap
$187.3M
Beta
1.63
P/E (TTM)
—
P/E (Fwd)
-1.94
EPS (TTM)
$-4.13
EPS (Fwd)
$-3.08
ROE
-59.2%
ROA
-37.4%
Cash
$220.0M
Total Debt
$569,000
Free CF
-$71.3M
52W Change
-85.0%
Annual Financials
Cash vs Debt
Where LENZ stands vs its 150-day and 200-day moving averages
As of the September 3, 2026 close, LENZ finished 31.52% below its 150-day moving average ($8.47) and 50.47% below its 200-day moving average ($11.71). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is LENZ overbought or oversold?
At the September 3, 2026 close, LENZ's RSI(14) was 80.9, in overbought territory (above 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The balance sheet looks solid with $220.0M in cash comfortably exceeding the $569K debt load. A net cash position generally provides financial flexibility during uncertain economic periods. The company is burning cash, with free cash flow at -$71.3M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. ROE of -59.2% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity.
LENZ Therapeutics, Inc.'s elevated beta suggests the stock experiences more pronounced price movements than the overall market, which increases both upside potential and downside risk. With cash comfortably exceeding debt, LENZ has financial flexibility that may help navigate uncertain periods. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence LENZ Therapeutics, Inc.'s trajectory.